OpenAlex Citation Counts

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
Romelia Barba, Bryan W. Ferrigno, Esli Medina Morales, et al.
The Turkish Journal of Gastroenterology (2023) Vol. 34, Iss. 2, pp. 89-100
Open Access | Times Cited: 16

Showing 16 citing articles:

Treatment of liver fibrosis: Past, current, and future
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 6, pp. 755-774
Open Access | Times Cited: 40

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 1

Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals
Lei Lei, Hu Li, Xuekai Wang, et al.
International Journal of Biological Sciences (2025) Vol. 21, Iss. 2, pp. 802-822
Open Access

Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments
Asad Ali Khan, Furqan Haq, Qazi Muhammad Farooq Wahab, et al.
Cureus (2025)
Open Access

Seladelpar for the Treatment of Primary Biliary Cholangitis
Adonice Khoury, Jason Powell
Annals of Pharmacotherapy (2025)
Closed Access

Autoimmune Disorders of the Liver and Biliary Tract
C. M. Anderson, Christopher L. Welle, Daniel Ludwig, et al.
Radiographics (2025) Vol. 45, Iss. 4
Closed Access

Clinical outcomes in patients with autoimmune hepatitis and primary biliary cholangitis overlap syndrome in the United States
Ritik M. Goyal, Bhavik Bansal, Mohammed Ayyad, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102598-102598
Open Access

Elafibranor (Iqirvo) unveiled: A groundbreaking FDA-approved therapy revolutionizing primary biliary cholangitis treatment
Iqra Furqan Ahmed, Fatima Rizwan, Haleema Mansoor, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 12, pp. 6910-6912
Open Access | Times Cited: 2

Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Nicholas Cumpian, Gina Choi, Sammy Saab
Digestive Diseases and Sciences (2024)
Closed Access | Times Cited: 2

The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients
Ana Marenco-Flores, Natalia Rojas Amaris, Tamara F. Kahan, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 15, pp. 4497-4497
Open Access | Times Cited: 1

NOTCH signalling – a core regulator of bile duct disease?
Anabel Martinez Lyons, Luke Boulter
Disease Models & Mechanisms (2023) Vol. 16, Iss. 9
Open Access | Times Cited: 2

Two Decades of Liver Transplants for Primary Biliary Cholangitis: A Comparative Study of Living Donors vs. Deceased Donor Liver Transplantations
Esli Medina‐Morales, Mohamed Ismail, Romelia Barba, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6536-6536
Open Access | Times Cited: 2

Autoimmune Biliary Diseases
Suzanne Evans, Alana Hofmann
Surgical Clinics of North America (2024) Vol. 104, Iss. 6, pp. 1249-1261
Closed Access

Elafibranor: a breakthrough therapy revolutionizing primary biliary cholangitis (PBC) treatment
Muhammad Hamza Gul, Aiman Waheed, Abdul Baseer Wardak, et al.
Annals of Medicine and Surgery (2024) Vol. 87, Iss. 2, pp. 454-456
Open Access

Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study
Dujinthan Jayabalan, Yi‐Hsiang Huang, Luis Calzadilla Bertot, et al.
Journal of Gastroenterology and Hepatology (2024)
Closed Access

Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis
Jawad Salamat Ali, Tauqeer Ali, Md. Al Hasibuzzaman
Annals of Medicine and Surgery (2024) Vol. 87, Iss. 1, pp. 30-32
Open Access

Page 1

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.

Requested Article:

Showing 16 citing articles:

Your Privacy